血浆微生物游离DNA测序直接检测耐药标志物的分析与临床验证
该研究对血浆微生物游离DNA测序直接检测18种病原体中7种耐药基因标志物进行了分析与临床验证。分析验证显示重现性100%、包容性54%至100%、排他性100%;临床准确性用114份血浆样本评估,报告了各标志物的阳性符合率、阴性符合率和诊断产出。该方法为优化治疗提供了不依赖培养的新工具。
要点
- 血浆mcfDNA测序可非侵入性检测7种耐药标志物并计算关联至18种病原体。
- 葡萄球菌SCCmec/mecA合并分析PPA 95.0%、NPA 95.4%、DY 70.0%。
- 革兰阴性杆菌blaKPC的PPA为0/2(0%)、NPA 100%、DY 56.8%。
核心结论
- 血浆mcfDNA测序直接检测耐药标志物经分析与临床验证,有望成为优化治疗的培养非依赖新工具。
研究设计与样本
- 分析与临床验证研究,临床准确性评估使用来自七个研究点的114份独特血浆样本,目标细菌培养结果一致。
主要发现
- 分析验证显示重现性100%、包容性54%至100%、排他性100%。
- 葡萄球菌SCCmec与mecA合并:PPA 19/20(95.0%)、NPA 21/22(95.4%)、DY 42/60(70.0%)。
- 肠球菌vanA:PPA 3/3(100%)、NPA 2/2(100%)、DY 5/6(83.3%)。
- 革兰阴性杆菌blaCTX-M:PPA 5/6(83.3%)、NPA 29/29(100%)、DY 35/49(71.4%)。
- 革兰阴性杆菌blaKPC:PPA 0/2(0%)、NPA 23/23(100%)、DY 25/44(56.8%)。
关键数值与推荐
- 检测的耐药标志物包括SCCmec、mecA、mecC、vanA、vanB、blaCTX-M和blaKPC,关联至18种重要病原体。
- 诊断产出(DY)定义为检测结果可报告为检出或未检出的测试百分比。
临床怎么用
- 该能力已纳入Karius检测工作流程(2023年9月),可用于优化抗微生物治疗。
- 工作流程可按需扩展目标细菌和耐药标志物数量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Sequencing of plasma microbial cell-free DNA (mcfDNA) has gained increased acceptance as a valuable adjunct to standard-of-care testing for diagnosis of infections throughout the body. Here, we report the analytical and clinical validation of a novel application of mcfDNA sequencing, the non-invasive detection of seven common antimicrobial resistance (AMR) genetic markers in 18 important pathogens. The AMR markers include SCCmec, mecA, mecC, vanA, vanB, blaCTX-M, and blaKPC. The AMR markers were computationally linked to the pathogens detected. Analytical validation showed high reproducibility (100%), inclusivity (54 to 100%), and exclusivity (100%). Clinical accuracy was assessed with 114 unique plasma samples from patients at seven study sites with concordant culture results for target bacteria from a variety of specimen types and correlated with available phenotypic antimicrobial susceptibility test results and genotypic results. The positive percent agreement (PPA), negative percent agreement (NPA), and diagnostic yield (DY) were estimated for each AMR marker. DY was defined as the percentage of tests that yielded an actionable result of either detected or not detected. The results for the combination of SCCmec and mecA for staphylococci were PPA 19/20 (95.0%), NPA 21/22 (95.4%), DY 42/60 (70.0%); vanA for enterococci were PPA 3/3 (100%), NPA 2/2 (100%), DY 5/6 (83.3%); blaCTX-M for gram-negative bacilli were PPA 5/6 (83.3%), NPA 29/29 (100%), DY 35/49 (71.4%); and blaKPC for gram-negative bacilli were PPA 0/2 (0%), NPA: 23/23 (100%), DY 25/44 (56.8%). The addition of AMR capability to plasma mcfDNA sequencing should provide clinicians with an effective new culture-independent tool for optimization of therapy. IMPORTANCE: This manuscript is ideally suited for the Innovative Diagnostic Methods sections as it reports the analytical and clinical validation of a novel application of plasma microbial cell-free DNA sequencing for direct detection of seven selected antimicrobial resistance markers in 18 target pathogens. Clearly, it has potential clinical utility in optimizing therapy and was incorporated into the Karius test workflow in September 2023. In addition, the workflow could readily be adapted to expand the number of target bacteria and antimicrobial resistance markers as needed.
引用
- Christians FC, Akhund-Zade J, Jarman K, et al. Analytical and clinical validation of direct detection of antimicrobial resistance markers by plasma microbial cell-free DNA sequencing. J Clin Microbiol. 2024. PMID: 39194269. doi:10.1128/jcm.00425-24
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。